**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 53658

**Manuscript Type:** REVIEW

**Vaccine therapy for dysbiosis-related diseases**

Fujimoto K *et al*. Vaccine therapy for dysbiosis-related diseases

Kosuke Fujimoto, Satoshi Uematsu

**Kosuke Fujimoto**, **Satoshi Uematsu**, Department of Immunology and Genomics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan

**Kosuke Fujimoto**, **Satoshi Uematsu**, Division of Innate Immune Regulation, International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan

**Satoshi Uematsu**, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan

**Satoshi Uematsu**, Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, Tokyo 113-8654, Japan

**Author contributions:** Fujimoto K and Uematsu S wrote the paper.

**Supported by** the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Grant-in-Aid for Early-Career Scientists), No. 19K17932 (To Fujimoto K).

**Corresponding author: Satoshi Uematsu, MD, PhD, Professor,** Department of Immunology and Genomics, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. uematsu.satoshi@med.osaka-cu.ac.jp

**Received:** December 27, 2019

**Revised:** March 27, 2020

**Accepted:** May 23, 2020

**Published online:** June 7, 2020

**Abstract**

Progress in genomic analysis has resulted in the proposal that the intestinal microbiota is a crucial environmental factor in the development of multifactorial diseases, such as obesity, diabetes, rheumatoid arthritis, and inflammatory bowel diseases represented by Crohn’s disease and ulcerative colitis. Dysregulated gut microbiome contributes to the pathogenesis of such disorders; however, there are few effective treatments for controlling only disease-mediating bacteria. Here, we review current knowledge about the intestinal microbiome in health and disease, and discuss a regulatory strategy using a parenteral vaccine with emulsified curdlan and CpG oligodeoxynucleotides, which we have recently developed. Unlike other conventional injectable immunizations, our vaccine contributes to the induction of antigen-specific systemic and mucosal immunity. This vaccine strategy can prevent infectious diseases such as *Streptococcus pneumoniae* infection, and control metabolic symptoms mediated by intestinal bacteria (*e.g.* *Clostridium ramosum*) by induction of high titers of antigen-specific IgA at target mucosal sites. In the future, our vaccination approach could be an effective therapy for common infectious diseases and dysbiosis-related disorders that have been difficult to control so far.

**Key words:** Dysbiosis; IgA; Microbiome; Mucosal immunity; Pathobiont; Vaccine

**Citation:** Fujimoto K, Uematsu S. Vaccine therapy for dysbiosis-related diseases. *World J Gastroenterol* 2020; 26(21): 2758-2767

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i21/2758.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i21.2758

**Core tip:** How to control intestinal pathogenic bacteria that mediate multifactorial diseases is a major concern worldwide. There are few methods for controlling only intestinal pathogenic bacteria; therefore, we have developed a prime–boost type, next-generation mucosal vaccine, and have used it for control of bacterial intestinal diseases. This vaccine can contribute to prevention of *Clostridium ramosum*-mediated obesity. Thus, this approach might be useful for protecting against microbe-associated disorders of the intestine.

**INTRODUCTION**

With the rapid progress of next-generation sequencing and genome analysis technology, human genome analysis has ended, and the focus has shifted to research on commensal microbiomes[1-8]. Body sites that are exposed to a wide variety of external antigens through mucosal sites, such as the respiratory organs and gastrointestinal tract, are constantly colonized with microorganisms, resulting in a symbiotic relationship. If this relationship is broken, the host immune response to microorganisms is distorted, sometimes causing disease. Dysbiosis, which is defined as an imbalance in the repertoire of the intestinal microbiota, is associated with many disorders in humans[9-11]. Therefore, novel strategies to control dysbiosis-associated diseases by attenuating the function of related microorganisms are necessary.

Antibiotics, which were first deployed in 1910, have drastically changed our lives[12]. In particular, penicillin discovered in 1928 contributed to the discovery of naturally occurring antibiotics. Antibiotics have extended our lifespans by > 20 years. However, a rapid increase in multidrug-resistant bacteria has arisen because of overuse and inappropriate consumption and application of antibiotics, which reveals that antibiotics are not a panacea for infectious diseases[13,14]. In addition, antibiotics sometimes cause dysbiosis and can lead to diseases such as *Clostridium difficile* (*C. difficile*) infection[15]. Thus, although antibiotics are available for killing disease-specific commensal bacteria, they are not suitable for eliminating only pathogens.

Fecal microbiota transplantation (FMT), an effective therapy for dysbiosis-related diseases such as *C. difficile* infection, has been shown to improve aberrant intestinal microbiota[16,17]. Feces from healthy individuals, which are considered relatively safe, are usually used for FMT. However, it was recently reported that antibiotic-resistant bacteria from donor feces were transferred to recipients and induced bacteremia[18]. This is an emergency issue and FMT is not now a recommended regimen. In fact, elimination of only pathobionts through the intestinal mucosa is difficult; therefore, development of novel methods to control dysbiosis-related diseases by attenuating the function of pathobionts is strongly desired.

In this review, we present current knowledge about the intestinal microbiome in health and disease, and discuss a prime–boost type, next-generation mucosal vaccine that we have recently developed and reported for control of disease mediated by intestinal bacteria.

**INTESTINAL MICROBIOME IN HEALTH AND DISEASE**

Intestinal commensal microbes have primarily been analyzed through single bacterial species isolation. Since most enteric bacteria do not like aerobic conditions, it has been difficult to culture them. However, advances in culture-independent technologies such as next-generation sequencing have shown the dynamics of the human intestinal microbiota[9,19]. For example, trillions of intestinal microbes reside in the gastrointestinal tract and dysbiosis is correlated with diseases such as obesity[20-22], diabetes[23-25], rheumatoid arthritis (RA)[26-31], and inflammatory bowel diseases (IBDs) including Crohn’s disease and ulcerative colitis[32]. Therefore, in addition to the current best treatment, it is suggested that controlling dysbiosis may improve these diseases.

It is widely accepted that metabolic diseases, such as obesity and diabetes, are intimately correlated with diet and dysbiosis[22,33]. Germ-free (GF) mice do not develop western-diet-induced obesity[34-36]. It was also shown in 2006 that colonization of GF mice with intestinal microbiota from obese mice led to a significantly greater increase in total body fat than colonization with microbiota from lean mice[21]. This suggests a strong association between the intestinal microbiota and host metabolism. The intestinal microbiome from obese mice and humans has a significantly higher ratio of Firmicutes to Bacteroidetes (F/B ratio) than that from their lean counterparts[21,37-40]. In addition, the bacterial diversity is lower in the microbiota from obese than lean individuals[39,41]. However, other studies have shown no difference in the F/B ratio between obese and lean individuals[42-46]. Therefore, although the diversity in obese individuals is low compared with that in lean individuals, the correlation between obesity and the F/B ratio is unclear.

There is an increased risk of developing type 2 diabetes in obesity; therefore, dysbiosis might also influence type 2 diabetes. Previous reports have shown that disorder of intestinal carbohydrate metabolism and low-grade gut inflammation cause insulin resistance[47-49]. A reduced abundance of short chain fatty acids such as butyrate is associated with type 2 diabetes[50]. Vrieze *et al*[51] showed that FMT improved insulin resistance in individuals with metabolic syndrome by altered levels of butyrate-producing intestinal bacteria, indicating that gut microorganisms might be developed as therapeutic tools in the future.

RA is a systemic inflammatory disorder including in polyarthritis that leads to joint destruction. Although both genetic and environmental factors are involved in the pathogenesis of RA, intestinal microbiota analysis has recently attracted much attention, along with single nucleotide polymorphism analysis. When mice are reared in GF conditions, arthritis does not develop, indicating that intestinal microbiota is related to onset of arthritis[28,52-54]. Abdollahi-Roodsaz *et al*[53] showed that interleukin-1 receptor antagonist knockout mice do not spontaneously develop T-cell-mediated arthritis under GF conditions. However, they do develop arthritis under specific-pathogen-free conditions, and monocolonization of the mice with *Lactobacillus bifidus* induces arthritis[53]. Matsumoto *et al*[55] also showed that K/BxN T-cell receptor transgenic mice develop arthritis under specific-pathogen-free conditions, but not GF conditions, and monocolonization of the mice with segmented filamentous bacteria induces arthritis. Previous studies have shown that composition of the microbiota is altered in early RA[26,28,56]. In the preclinical stages of RA, *Prevotella* species such as *Prevotella copri* (*P. copri*) are dominant in the intestine. Maeda *et al*[28] showed that microbiota isolated from RA patients whose fecal bacteria contained high levels of *P. copri* contributes to the development of Th17-dependent arthritis, and monocolonization of SKG mice with *P. copri* is sufficient to induce arthritis. Thus, although more precise investigations are needed to determine which bacterium is a target for RA treatment, it is strongly suggested that there are intestinal pathogens that are related to the pathogenesis of human RA.

IBDs are increasing in incidence worldwide[57]. Also in Japan, the numbers of IBD patients have rapidly increased over the past 30 years, suggesting that in addition to genetic predisposition, environmental factors such as dysbiosis are more involved in the development of IBDs[58]. Various changes in the intestinal microbiota have been reported in IBD patients[59-61]. The advent of next-generation sequencing has revealed a range of altered microbiota in the intestine. However, a common problem is that it is unclear whether the dysbiosis observed in IBD patients is a cause or a consequence of intestinal inflammation. Given the complicated relationships between the intestinal immune system and gut microbiota, further studies are needed to elucidate the pathogenesis of IBDs and develop more effective treatments.

**PRIME–BOOST TYPE MUCOSAL VACCINE**

Conventional injectable vaccines, including subcutaneous vaccines, have the ability to induce antigen-specific IgG, maintain antigen-specific immune memory, and contribute to prevention of severe infection[62-64]. Pediatric vaccination is a key factor in protection against many life-threatening infections[64]. However, despite progress in vaccine technology, many infections remain incompletely controlled in both humans and animals worldwide.

Mucosal immune responses are thought to be effective for prevention of infection because foreign antigens, such as microorganisms and food antigens, enter the host through mucosal surfaces[65-69]. In the mucosal sites, secretory IgA (SIgA) plays an important role in regulating intestinal health and disease prevention[70-78]. The major functions of IgA are (1) prevention of adherence, colonization, and invasion of pathogenic microorganisms that invade the mucosal surface; (2) neutralizing effect on toxins and enzymes produced by pathogenic microorganisms; (3) capturing pathogenic microorganisms in the mucus layer; and (4) antimicrobial activity. Only limited numbers of mucosal vaccines are available to date; therefore, a new mucosal vaccine strategy is strongly desired for induction of beneficial systemic immune responses.

IgA is the most abundant antibody in mucosal secretory components. In the intestinal mucosa, there are two types of IgA production mechanisms, represented by T-cell-dependent and T-cell-independent immune responses[79-82]. In the gut, T-cell-dependent antibody responses are involved in activation of B cells by antigen in the organized lymphoid tissue of Peyer’s patches, mesenteric lymph nodes and isolated lymphoid follicles[82-84]. It has been shown that both CD40L and transforming growth factor-β1 are essential for the induction of T-cell-dependent IgA class switching[85]. In contrast, T-cell-independent IgA class switch recombination occurs in B1 cells of the gut-associated lymphoid tissue (GALT), where IgA is constitutively induced by stimulation with commensal bacteria[82].

GALT, such as Peyer’s patches and isolated lymphoid follicles, is the primary site for IgA induction[86,87]. It has been reported that antigen-specific IgA-producing B cells develop in GALTs with the aid of GALT-dendritic cells (DCs). It is notable that retinoic acid synthesized by GALT-DCs can contribute to IgA synthesis[87-89]. GALT-DCs are also able to imprint gut-homing chemokine receptors such as α4β7 integrin and C-C chemokine receptor type 9 on B and T cells, which is an essential process for lymphocyte migration to the intestines[90].

Intestinal lamina propria DCs (LPDCs) are also crucial inducers of SIgA-producing B cells in a T-cell-independent manner. We have previously reported two subsets of small-intestinal LPDCs based on their differential CD11c and CD11b expression patterns: CD11chiCD11blo LPDCs and CD11chiCD11bhi LPDCs[91-93] (Figure 1). CD11chiCD11bhi intestinal LPDCs express the gene encoding the retinoic-acid-converting enzyme, *Raldh2*, and are able to induce antigen-specific SIgA as well as systemic immunity mediated by Toll-like receptor (TLR) 5 or 9 stimulation[91] (Figure 1). In contrast to CD11chiCD11bhi LPDCs, CD11chiCD11blo LPDCs express TLR3, TLR7 and TLR9, which recognize dsRNA, ssRNA, and CpG oligodeoxynucleotides (ODNs), respectively[93] (Figure 1). They do not express *Raldh2* and are not involved in IgA synthesis in the small-intestinal lamina propria[93]. In addition, high titers of antigen-specific IgA were detected in fecal extracts from antigen-loaded CD11chiCD11bhi LPDC-immunized mice[93]. Accordingly, CD11chiCD11bhi LPDCs are considered to be an ideal target for a mucosal vaccine, but it has thus far been technically difficult to induce antigen-specific mucosal immunity using conventional injectable vaccines.

We have recently reported that splenic DCs stimulated with both curdlan, dectin-1 ligand, and CpG-ODN, TLR9 ligand, successfully induced antigen-specific fecal IgA as well as antigen-specific serum IgG and splenic Th1 and Th17 responses in mice[94]. This indicates that combination of curdlan and CpG-ODN is available as an adjuvant of parenteral vaccination to induce broad functional immunity against mucosal antigens. We found that intramuscular immunization with the combination of curdlan and CpG-ODN emulsified with incomplete Freund’s adjuvant induced antigen-specific fecal IgA as well as serum IgG and splenic Th1 and Th17 responses[94] (Figure 2). However, although antigen-specific IgG in serum was continuously detected after prime injection, antigen-specific IgA production in feces was only transiently detected by parenteral immunization with curdlan + CpG-ODN[94]. Therefore, additional immunization, for example, boosting, to induce more durable mucosal immunity at targeted mucosal sites is thought to be necessary. We have demonstrated that after oral, nasal or vaginal antigen administration, high titers of long-lasting antigen-specific intestinal, lung or vaginal IgA are inducible[94] (Figure 2). Also, this prime–boost vaccine is effective against cholera-toxin-induced diarrhea and *Streptococcus pneumoniae* (*S. pneumoniae*) infection[94]. Thus, we established intramuscular antigen injection adjuvanted with curdlan + CpG-ODN and subsequent antigen administration on target mucosal sites (prime–boost vaccination) as a new vaccine strategy capable of inducing strong and durable systemic and mucosal immunity.

**FUTURE REGULATION OF DYSBIOSIS-ASSOCIATED DISORDERS**

Intestinal dysfunction has been correlated with multifactorial diseases[9], suggesting that the mucosal immune responses provide a solid causal link between pathological symptoms in the host and disease-associated dysbiosis. Several studies have identified some pathobionts, such as *Clostridium ramosum* (*C. ramosum*)[95], *P. copri*[26,28], *Helicobacter pylori*[96], adherent invasive *Escherichia coli*[97], *Clostridium scindens*[98], and *Enterococcus gallinarum*[99]. Therefore, regulating the function of disease-associated pathobionts can lead to prevention or treatment of dysbiosis-related disorders. However, antibiotics are not suitable for eliminating only pathogens because they have the possibility to induce dysbiosis or multidrug-resistant bacteria[100].

*C. ramosum* is an obligate anaerobic bacterium first identified in an appendicitis patient in 1898 and widely inhabits the human gastrointestinal tract. Increased levels of *C. ramosum* are associated with human obesity and diabetes[20,23]. *C. ramosum* is also associated with clinical symptoms of metabolic disorders in gnotobiotic mice colonized with *C. ramosum* alone and a simplified human intestinal microbiome containing *C. ramosum*. Furthermore, it has been shown that the numbers of *C. ramosum* are higher in mice fed a high-fat compared with normal-fat diet, and this results in increased expression of *Slc2a2* in the small-intestinal mucosa[95]. Therefore, we recently applied our prime–boost vaccination to control *C. ramosum*-mediated diseases. Our vaccine for *C. ramosum* significantly inhibited body weight gain and the increased levels of *C. ramosum* in the intestinal mucosa under a high-fat diet[94]. It also resulted in decreased expression of *Slc2a2* and subsequently ameliorated glucose intolerance[94]. It is notable that this immunization strategy did not induce dysbiosis[94]. Thus, it might be effective for preventing *C. ramosum*-associated obesity and diabetes.

Until now, there have been few methods that can induce high titers of antigen-specific IgA at target mucosal sites using an injection-type mucosal vaccine. It is noteworthy that we have developed a next-generation prime–boost mucosal vaccine using curdlan and CpG-ODN, and used it for control of diseases such as *S. pneumoniae* infection, and other diseases mediated by intestinal bacteria[94]. With the advent of gnotobiotic technology, function of the intestinal microbiome has been revealed. However, since there are few methods for specifically attenuating the function of intestinal bacteria, many diseases mediated by intestinal bacteria are still not fully elucidated. Our vaccination is the world’s first immunization strategy, and has the potential to be an excellent technique for functional analysis of intestinal bacteria.

**CONCLUSION**

As the link between various diseases and aberrant intestinal microbiota becomes apparent, there is an urgent need to develop and disseminate control strategies for dysbiosis in addition to existing effective treatments. Antibiotics are not specific to pathobionts and may induce dysbiosis that can lead to disease. Attempts have also been made to control diseases mediated by intestinal bacteria using FMT or probiotic treatments, but these are established and effective treatments. An important treatment for diseases mediated by intestinal bacteria is to improve the underlying disease without inducing new dysbiosis. Vaccination with curdlan + CpG-ODN and antigens and subsequent antigen administration can effectively induce antigen-specific systemic and mucosal immunity. This prime–boost vaccine method has been patented in Japan and prime–boost vaccines targeting various infectious diseases are being developed for future human prescription. There is no doubt that the vaccine technology discussed in this review will become a new treatment in the next generation of antimicrobial strategies. Further analysis of the gut microbiota is necessary, but we are eagerly looking forward to developing pathobiont-specific treatments for human diseases in the future.

**ACKNOWLEDGEMENTS**

We thank K Ogawa, M Maeda, and K Suetsugu for secretarial assistance.

**REFERENCES**

1 **Cho I**, Blaser MJ. The human microbiome: at the interface of health and disease. *Nat Rev Genet* 2012; **13**: 260-270 [PMID: 22411464 DOI: 10.1038/nrg3182]

2 **Gajer P**, Brotman RM, Bai G, Sakamoto J, Schütte UM, Zhong X, Koenig SS, Fu L, Ma ZS, Zhou X, Abdo Z, Forney LJ, Ravel J. Temporal dynamics of the human vaginal microbiota. *Sci Transl Med* 2012; **4**: 132ra52 [PMID: 22553250 DOI: 10.1126/scitranslmed.3003605]

3 **Kinross JM**, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. *Genome Med* 2011; **3**: 14 [PMID: 21392406 DOI: 10.1186/gm228]

4 **Lynch SV**, Pedersen O. The Human Intestinal Microbiome in Health and Disease. *N Engl J Med* 2016; **375**: 2369-2379 [PMID: 27974040 DOI: 10.1056/NEJMra1600266]

5 **Ma B**, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. *Annu Rev Microbiol* 2012; **66**: 371-389 [PMID: 22746335 DOI: 10.1146/annurev-micro-092611-150157]

6 **Pflughoeft KJ**, Versalovic J. Human microbiome in health and disease. *Annu Rev Pathol* 2012; **7**: 99-122 [PMID: 21910623 DOI: 10.1146/annurev-pathol-011811-132421]

7 **Wade WG**. The oral microbiome in health and disease. *Pharmacol Res* 2013; **69**: 137-143 [PMID: 23201354 DOI: 10.1016/j.phrs.2012.11.006]

8 **Shreiner AB**, Kao JY, Young VB. The gut microbiome in health and in disease. *Curr Opin Gastroenterol* 2015; **31**: 69-75 [PMID: 25394236 DOI: 10.1097/MOG.0000000000000139]

9 **Gilbert JA**, Quinn RA, Debelius J, Xu ZZ, Morton J, Garg N, Jansson JK, Dorrestein PC, Knight R. Microbiome-wide association studies link dynamic microbial consortia to disease. *Nature* 2016; **535**: 94-103 [PMID: 27383984 DOI: 10.1038/nature18850]

10 **Mirzaei MK**, Maurice CF. Ménage à trois in the human gut: interactions between host, bacteria and phages. *Nat Rev Microbiol* 2017; **15**: 397-408 [PMID: 28461690 DOI: 10.1038/nrmicro.2017.30]

11 **Rooks MG**, Garrett WS. Gut microbiota, metabolites and host immunity. *Nat Rev Immunol* 2016; **16**: 341-352 [PMID: 27231050 DOI: 10.1038/nri.2016.42]

12 **Hutchings MI**, Truman AW, Wilkinson B. Antibiotics: past, present and future. *Curr Opin Microbiol* 2019; **51**: 72-80 [PMID: 31733401 DOI: 10.1016/j.mib.2019.10.008]

13 **Molton JS**, Tambyah PA, Ang BS, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. *Clin Infect Dis* 2013; **56**: 1310-1318 [PMID: 23334810 DOI: 10.1093/cid/cit020]

14 **Magiorakos AP**, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012; **18**: 268-281 [PMID: 21793988 DOI: 10.1111/j.1469-0691.2011.03570.x]

15 **Antharam VC**, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. *J Clin Microbiol* 2013; **51**: 2884-2892 [PMID: 23804381 DOI: 10.1128/JCM.00845-13]

16 **Bakken JS**, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. *Clin Gastroenterol Hepatol* 2011; **9**: 1044-1049 [PMID: 21871249 DOI: 10.1016/j.cgh.2011.08.014]

17 **Borody TJ**, Khoruts A. Fecal microbiota transplantation and emerging applications. *Nat Rev Gastroenterol Hepatol* 2011; **9**: 88-96 [PMID: 22183182 DOI: 10.1038/nrgastro.2011.244]

18 **DeFilipp Z**, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL. Drug-Resistant *E. coli* Bacteremia Transmitted by Fecal Microbiota Transplant. *N Engl J Med* 2019; **381**: 2043-2050 [PMID: 31665575 DOI: 10.1056/NEJMoa1910437]

19 **Thaiss CA**, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. *Nature* 2016; **535**: 65-74 [PMID: 27383981 DOI: 10.1038/nature18847]

20 **Le Chatelier E**, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. *Nature* 2013; **500**: 541-546 [PMID: 23985870 DOI: 10.1038/nature12506]

21 **Turnbaugh PJ**, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006; **444**: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]

22 **Sonnenburg JL**, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. *Nature* 2016; **535**: 56-64 [PMID: 27383980 DOI: 10.1038/nature18846]

23 **Karlsson FH**, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature* 2013; **498**: 99-103 [PMID: 23719380 DOI: 10.1038/nature12198]

24 **Kostic AD**, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen AM, Peet A, Tillmann V, Pöhö P, Mattila I, Lähdesmäki H, Franzosa EA, Vaarala O, de Goffau M, Harmsen H, Ilonen J, Virtanen SM, Clish CB, Orešič M, Huttenhower C, Knip M; DIABIMMUNE Study Group, Xavier RJ. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. *Cell Host Microbe* 2015; **17**: 260-273 [PMID: 25662751 DOI: 10.1016/j.chom.2015.01.001]

25 **Wen L**, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature* 2008; **455**: 1109-1113 [PMID: 18806780 DOI: 10.1038/nature07336]

26 **Scher JU**, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. *Elife* 2013; **2**: e01202 [PMID: 24192039 DOI: 10.7554/eLife.01202]

27 **Scher JU**, Joshua V, Artacho A, Abdollahi-Roodsaz S, Öckinger J, Kullberg S, Sköld M, Eklund A, Grunewald J, Clemente JC, Ubeda C, Segal LN, Catrina AI. The lung microbiota in early rheumatoid arthritis and autoimmunity. *Microbiome* 2016; **4**: 60 [PMID: 27855721 DOI: 10.1186/s40168-016-0206-x]

28 **Maeda Y**, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K, Hirota K, Matsushita M, Furuta Y, Narazaki M, Sakaguchi N, Kayama H, Nakamura S, Iida T, Saeki Y, Kumanogoh A, Sakaguchi S, Takeda K. Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. *Arthritis Rheumatol* 2016; **68**: 2646-2661 [PMID: 27333153 DOI: 10.1002/art.39783]

29 **Phillips R**. Rheumatoid arthritis: Microbiome reflects status of RA and response to therapy. *Nat Rev Rheumatol* 2015; **11**: 502 [PMID: 26241185 DOI: 10.1038/nrrheum.2015.109]

30 **Kishikawa T**, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M, Matsuoka H, Yoshimura M, Kawada S, Teshigawara S, Oguro E, Okita Y, Kawamoto K, Higa S, Hirano T, Narazaki M, Ogata A, Saeki Y, Nakamura S, Inohara H, Kumanogoh A, Takeda K, Okada Y. Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. *Ann Rheum Dis* 2020; **79**: 103-111 [PMID: 31699813 DOI: 10.1136/annrheumdis-2019-215743]

31 **Maeda Y**, Takeda K. Host-microbiota interactions in rheumatoid arthritis. *Exp Mol Med* 2019; **51**: 1-6 [PMID: 31827063 DOI: 10.1038/s12276-019-0283-6]

32 **Rigottier-Gois L**. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. *ISME J* 2013; **7**: 1256-1261 [PMID: 23677008 DOI: 10.1038/ismej.2013.80]

33 **Zhao L**. The gut microbiota and obesity: from correlation to causality. *Nat Rev Microbiol* 2013; **11**: 639-647 [PMID: 23912213 DOI: 10.1038/nrmicro3089]

34 **Bäckhed F**, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc Natl Acad Sci* USA 2007; **104**: 979-984 [PMID: 17210919 DOI: 10.1073/pnas.0605374104]

35 **Ding S**, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, Jobin C, Lund PK. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. *PLoS One* 2010; **5**: e12191 [PMID: 20808947 DOI: 10.1371/journal.pone.0012191]

36 **Rabot S**, Membrez M, Bruneau A, Gérard P, Harach T, Moser M, Raymond F, Mansourian R, Chou CJ. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. *FASEB J* 2010; **24**: 4948-4959 [PMID: 20724524 DOI: 10.1096/fj.10-164921]

37 **Ley RE**, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* 2005; **102**: 11070-11075 [PMID: 16033867 DOI: 10.1073/pnas.0504978102]

38 **Ley RE**, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006; **444**: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]

39 **Turnbaugh PJ**, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. *Nature* 2009; **457**: 480-484 [PMID: 19043404 DOI: 10.1038/nature07540]

40 **Zhang H**, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. Human gut microbiota in obesity and after gastric bypass. *Proc Natl Acad Sci U S A* 2009; **106**: 2365-2370 [PMID: 19164560 DOI: 10.1073/pnas.0812600106]

41 **Turnbaugh PJ**, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. *Cell Host Microbe* 2008; **3**: 213-223 [PMID: 18407065 DOI: 10.1016/j.chom.2008.02.015]

42 **Schwiertz A**, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, Hardt PD. Microbiota and SCFA in lean and overweight healthy subjects. *Obesity (Silver Spring)* 2010; **18**: 190-195 [PMID: 19498350 DOI: 10.1038/oby.2009.167]

43 **Jumpertz R**, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Krakoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. *Am J Clin Nutr* 2011; **94**: 58-65 [PMID: 21543530 DOI: 10.3945/ajcn.110.010132]

44 **Balamurugan R**, George G, Kabeerdoss J, Hepsiba J, Chandragunasekaran AM, Ramakrishna BS. Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children. *Br J Nutr* 2010; **103**: 335-338 [PMID: 19849869 DOI: 10.1017/S0007114509992182]

45 **Zhang C**, Zhang M, Pang X, Zhao Y, Wang L, Zhao L. Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. *ISME J* 2012; **6**: 1848-1857 [PMID: 22495068 DOI: 10.1038/ismej.2012.27]

46 **Zhang C**, Zhang M, Wang S, Han R, Cao Y, Hua W, Mao Y, Zhang X, Pang X, Wei C, Zhao G, Chen Y, Zhao L. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. *ISME J* 2010; **4**: 232-241 [PMID: 19865183 DOI: 10.1038/ismej.2009.112]

47 **van Olden C**, Groen AK, Nieuwdorp M. Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus. *Clin Ther* 2015; **37**: 1172-1177 [PMID: 25922340 DOI: 10.1016/j.clinthera.2015.03.008]

48 **Devaraj S**, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. *Clin Chem* 2013; **59**: 617-628 [PMID: 23401286 DOI: 10.1373/clinchem.2012.187617]

49 **Perry RJ**, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, Petersen KF, Kibbey RG, Goodman AL, Shulman GI. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. *Nature* 2016; **534**: 213-217 [PMID: 27279214 DOI: 10.1038/nature18309]

50 **Komaroff AL**. The Microbiome and Risk for Obesity and Diabetes. *JAMA* 2017; **317**: 355-356 [PMID: 28006047 DOI: 10.1001/jama.2016.20099]

51 **Vrieze A**, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 2012; **143**: 913-6.e7 [PMID: 22728514 DOI: 10.1053/j.gastro.2012.06.031]

52 **Wu HJ**, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* 2010; **32**: 815-827 [PMID: 20620945 DOI: 10.1016/j.immuni.2010.06.001]

53 **Abdollahi-Roodsaz S**, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. *J Clin Invest* 2008; **118**: 205-216 [PMID: 18060042 DOI: 10.1172/JCI32639]

54 **Rehaume LM**, Mondot S, Aguirre de Cárcer D, Velasco J, Benham H, Hasnain SZ, Bowman J, Ruutu M, Hansbro PM, McGuckin MA, Morrison M, Thomas R. ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice. *Arthritis Rheumatol* 2014; **66**: 2780-2792 [PMID: 25048686 DOI: 10.1002/art.38773]

55 **Matsumoto I**, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. *Science* 1999; **286**: 1732-1735 [PMID: 10576739 DOI: 10.1126/science.286.5445.1732]

56 **Alpizar-Rodriguez D**, Lesker TR, Gronow A, Gilbert B, Raemy E, Lamacchia C, Gabay C, Finckh A, Strowig T. *Prevotella copri* in individuals at risk for rheumatoid arthritis. *Ann Rheum Dis* 2019; **78**: 590-593 [PMID: 30760471 DOI: 10.1136/annrheumdis-2018-214514]

57 **Ni J**, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? *Nat Rev Gastroenterol Hepatol* 2017; **14**: 573-584 [PMID: 28743984 DOI: 10.1038/nrgastro.2017.88]

58 **Matsuoka K**, Kanai T. The gut microbiota and inflammatory bowel disease. *Semin Immunopathol* 2015; **37**: 47-55 [PMID: 25420450 DOI: 10.1007/s00281-014-0454-4]

59 **Frank DN**, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 2007; **104**: 13780-13785 [PMID: 17699621 DOI: 10.1073/pnas.0706625104]

60 **Manichanh C**, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* 2006; **55**: 205-211 [PMID: 16188921 DOI: 10.1136/gut.2005.073817]

61 **Willing BP**, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. *Gastroenterology* 2010; **139**: 1844-1854.e1 [PMID: 20816835 DOI: 10.1053/j.gastro.2010.08.049]

62 **Nabel GJ**. Designing tomorrow's vaccines. *N Engl J Med* 2013; **368**: 551-560 [PMID: 23388006 DOI: 10.1056/NEJMra1204186]

63 **Omer SB**, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. *N Engl J Med* 2009; **360**: 1981-1988 [PMID: 19420367 DOI: 10.1056/NEJMsa0806477]

64 **Mascola JR**, Fauci AS. Novel vaccine technologies for the 21st century. *Nat Rev Immunol* 2020; **20**: 87-88 [PMID: 31712767 DOI: 10.1038/s41577-019-0243-3]

65 **Ganz T**. Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol* 2003; **3**: 710-720 [PMID: 12949495 DOI: 10.1038/nri1180]

66 **Marchiando AM**, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. *Annu Rev Pathol* 2010; **5**: 119-144 [PMID: 20078218 DOI: 10.1146/annurev.pathol.4.110807.092135]

67 **Peterson LW**, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. *Nat Rev Immunol* 2014; **14**: 141-153 [PMID: 24566914 DOI: 10.1038/nri3608]

68 **Helander HF**, Fändriks L. Surface area of the digestive tract - revisited. *Scand J Gastroenterol* 2014; **49**: 681-689 [PMID: 24694282 DOI: 10.3109/00365521.2014.898326]

69 **Goto Y**, Uematsu S, Kiyono H. Epithelial glycosylation in gut homeostasis and inflammation. *Nat Immunol* 2016; **17**: 1244-1251 [PMID: 27760104 DOI: 10.1038/ni.3587]

70 **Wang N**, Shen N, Vyse TJ, Anand V, Gunnarson I, Sturfelt G, Rantapää-Dahlqvist S, Elvin K, Truedsson L, Andersson BA, Dahle C, Ortqvist E, Gregersen PK, Behrens TW, Hammarström L. Selective IgA deficiency in autoimmune diseases. *Mol Med* 2011; **17**: 1383-1396 [PMID: 21826374 DOI: 10.2119/molmed.2011.00195]

71 **Mirpuri J**, Raetz M, Sturge CR, Wilhelm CL, Benson A, Savani RC, Hooper LV, Yarovinsky F. Proteobacteria-specific IgA regulates maturation of the intestinal microbiota. *Gut Microbes* 2014; **5**: 28-39 [PMID: 24637807 DOI: 10.4161/gmic.26489]

72 **Jarchum I**, Pamer EG. Regulation of innate and adaptive immunity by the commensal microbiota. *Curr Opin Immunol* 2011; **23**: 353-360 [PMID: 21466955 DOI: 10.1016/j.coi.2011.03.001]

73 **Palm NW**, de Zoete MR, Flavell RA. Immune-microbiota interactions in health and disease. *Clin Immunol* 2015; **159**: 122-127 [PMID: 26141651 DOI: 10.1016/j.clim.2015.05.014]

74 **Kubinak JL**, Petersen C, Stephens WZ, Soto R, Bake E, O'Connell RM, Round JL. MyD88 signaling in T cells directs IgA-mediated control of the microbiota to promote health. *Cell Host Microbe* 2015; **17**: 153-163 [PMID: 25620548 DOI: 10.1016/j.chom.2014.12.009]

75 **Round JL**, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 2009; **9**: 313-323 [PMID: 19343057 DOI: 10.1038/nri2515]

76 **Spencer J**, Klavinskis LS, Fraser LD. The human intestinal IgA response; burning questions. *Front Immunol* 2012; **3**: 108 [PMID: 22593756 DOI: 10.3389/fimmu.2012.00108]

77 **Lycke NY**, Bemark M. The regulation of gut mucosal IgA B-cell responses: recent developments. *Mucosal Immunol* 2017; **10**: 1361-1374 [PMID: 28745325 DOI: 10.1038/mi.2017.62]

78 **Pabst O**, Slack E. IgA and the intestinal microbiota: the importance of being specific. *Mucosal Immunol* 2020; **13**: 12-21 [PMID: 31740744 DOI: 10.1038/s41385-019-0227-4]

79 **Cerutti A**. The regulation of IgA class switching. *Nat Rev Immunol* 2008; **8**: 421-434 [PMID: 18483500 DOI: 10.1038/nri2322]

80 **Fagarasan S**, Honjo T. T-Independent immune response: new aspects of B cell biology. *Science* 2000; **290**: 89-92 [PMID: 11021805 DOI: 10.1126/science.290.5489.89]

81 **Fagarasan S**, Kawamoto S, Kanagawa O, Suzuki K. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. *Annu Rev Immunol* 2010; **28**: 243-273 [PMID: 20192805 DOI: 10.1146/annurev-immunol-030409-101314]

82 **Macpherson AJ**, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. *Science* 2000; **288**: 2222-2226 [PMID: 10864873 DOI: 10.1126/science.288.5474.2222]

83 **Tezuka H**, Abe Y, Asano J, Sato T, Liu J, Iwata M, Ohteki T. Prominent role for plasmacytoid dendritic cells in mucosal T cell-independent IgA induction. *Immunity* 2011; **34**: 247-257 [PMID: 21333555 DOI: 10.1016/j.immuni.2011.02.002]

84 **Bunker JJ**, Flynn TM, Koval JC, Shaw DG, Meisel M, McDonald BD, Ishizuka IE, Dent AL, Wilson PC, Jabri B, Antonopoulos DA, Bendelac A. Innate and Adaptive Humoral Responses Coat Distinct Commensal Bacteria with Immunoglobulin A. *Immunity* 2015; **43**: 541-553 [PMID: 26320660 DOI: 10.1016/j.immuni.2015.08.007]

85 **Macpherson AJ**, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. *Mucosal Immunol* 2008; **1**: 11-22 [PMID: 19079156 DOI: 10.1038/mi.2007.6]

86 **Chorny A**, Puga I, Cerutti A. Innate signaling networks in mucosal IgA class switching. *Adv Immunol* 2010; **107**: 31-69 [PMID: 21034970 DOI: 10.1016/B978-0-12-381300-8.00002-2]

87 **Suzuki K**, Kawamoto S, Maruya M, Fagarasan S. GALT: organization and dynamics leading to IgA synthesis. *Adv Immunol* 2010; **107**: 153-185 [PMID: 21034974 DOI: 10.1016/B978-0-12-381300-8.00006-X]

88 **Sutherland DB**, Fagarasan S. IgA synthesis: a form of functional immune adaptation extending beyond gut. *Curr Opin Immunol* 2012; **24**: 261-268 [PMID: 22503962 DOI: 10.1016/j.coi.2012.03.005]

89 **Pabst O**. New concepts in the generation and functions of IgA. *Nat Rev Immunol* 2012; **12**: 821-832 [PMID: 23103985 DOI: 10.1038/nri3322]

90 **Mora JR**, Iwata M, Eksteen B, Song SY, Junt T, Senman B, Otipoby KL, Yokota A, Takeuchi H, Ricciardi-Castagnoli P, Rajewsky K, Adams DH, von Andrian UH. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. *Science* 2006; **314**: 1157-1160 [PMID: 17110582 DOI: 10.1126/science.1132742]

91 **Uematsu S**, Fujimoto K, Jang MH, Yang BG, Jung YJ, Nishiyama M, Sato S, Tsujimura T, Yamamoto M, Yokota Y, Kiyono H, Miyasaka M, Ishii KJ, Akira S. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. *Nat Immunol* 2008; **9**: 769-776 [PMID: 18516037 DOI: 10.1038/ni.1622]

92 **Uematsu S**, Fujimoto K. The innate immune system in the intestine. *Microbiol Immunol* 2010; **54**: 645-657 [PMID: 21044138 DOI: 10.1111/j.1348-0421.2010.00267.x]

93 **Fujimoto K**, Karuppuchamy T, Takemura N, Shimohigoshi M, Machida T, Haseda Y, Aoshi T, Ishii KJ, Akira S, Uematsu S. A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. *J Immunol* 2011; **186**: 6287-6295 [PMID: 21525388 DOI: 10.4049/jimmunol.1004036]

94 **Fujimoto K**, Kawaguchi Y, Shimohigoshi M, Gotoh Y, Nakano Y, Usui Y, Hayashi T, Kimura Y, Uematsu M, Yamamoto T, Akeda Y, Rhee JH, Yuki Y, Ishii KJ, Crowe SE, Ernst PB, Kiyono H, Uematsu S. Antigen-Specific Mucosal Immunity Regulates Development of Intestinal Bacteria-Mediated Diseases. *Gastroenterology* 2019; **157**: 1530-1543.e4 [PMID: 31445037 DOI: 10.1053/j.gastro.2019.08.021]

95 **Woting A**, Pfeiffer N, Loh G, Klaus S, Blaut M. Clostridium ramosum promotes high-fat diet-induced obesity in gnotobiotic mouse models. *mBio* 2014; **5**: e01530-e01514 [PMID: 25271283 DOI: 10.1128/mBio.01530-14]

96 **Moyat M**, Velin D. Immune responses to Helicobacter pylori infection. *World J Gastroenterol* 2014; **20**: 5583-5593 [PMID: 24914318 DOI: 10.3748/wjg.v20.i19.5583]

97 **Barrios-Villa E**, Martínez de la Peña CF, Lozano-Zaraín P, Cevallos MA, Torres C, Torres AG, Rocha-Gracia RDC. Comparative genomics of a subset of Adherent/Invasive Escherichia coli strains isolated from individuals without inflammatory bowel disease. *Genomics* 2020; **112**: 1813-1820 [PMID: 31689478 DOI: 10.1016/j.ygeno.2019.10.013]

98 **Greathouse KL**, Harris CC, Bultman SJ. Dysfunctional families: Clostridium scindens and secondary bile acids inhibit the growth of Clostridium difficile. *Cell Metab* 2015; **21**: 9-10 [PMID: 25565200 DOI: 10.1016/j.cmet.2014.12.016]

99 **Manfredo Vieira S**, Hiltensperger M, Kumar V, Zegarra-Ruiz D, Dehner C, Khan N, Costa FRC, Tiniakou E, Greiling T, Ruff W, Barbieri A, Kriegel C, Mehta SS, Knight JR, Jain D, Goodman AL, Kriegel MA. Translocation of a gut pathobiont drives autoimmunity in mice and humans. *Science* 2018; **359**: 1156-1161 [PMID: 29590047 DOI: 10.1126/science.aar7201]

100 **Zaman SB**, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A Review on Antibiotic Resistance: Alarm Bells are Ringing. *Cureus* 2017; **9**: e1403 [PMID: 28852600 DOI: 10.7759/cureus.1403]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** December 27, 2019

**First decision:** February 14, 2020

**Article in press:** May 23, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P- Reviewer:** Abushady EAE **S- Editor:** Wang JL **L- Editor: A**  **E- Editor:** Ma YJ

**Figure Legends**



**Figure 1 Function of two distinct lamina propria dendritic cells in the small intestine.** Mouse small-intestinal lamina propria dendritic cells (LPDCs) are divided into two subsets on the basis of CD11c and CD11b expression. CD11chiCD11blo LPDCs express Toll-like receptor (TLR) 3, TLR7 and TLR9, whereas CD11chiCD11bhi LPDCs express TLR5 and TLR9. After TLR stimulation, activated CD11chiCD11bhi LPDCs can produce interleukin (IL)-12p40, IL-6, transforming growth factor-β and retinoic acid, and subsequently induce antigen-specific Th1 and Th17 responses and antigen-specific-IgA-producing plasma cells. In contrast to CD11chiCD11bhi LPDCs, activated CD11chiCD11blo LPDCs can induce antigen-specific Th1 responses, but not antigen-specific Th17 responses and antigen-specific-IgA-producing plasma cells. TLR: Toll-like receptor; TGF: Transforming growth factor; IL: Interleukin; DC: Dendritic cells.



**Figure 2 Scheme of antigen-specific immune responses by prime–boost vaccination.** Parenteral immunization with antigen emulsified in curdlan and CpG-oligodeoxynucleotides induces antigen-specific fecal IgA as well as serum IgG and splenic Th1 and Th17 responses. Once primed, high titers of long-lasting antigen-specific lung, intestinal, or vaginal IgA are induced after nasal, oral, or vaginal antigen administration, respectively. Also, antigen-specific Th1 and Th17 responses are induced at the targeted organs. CpG-ODN: CpG oligodeoxynucleotides.